LitCovid-sample-Enju  

PMC:7228307 / 33797-59627 JSONTXT 26 Projects

Annnotations TAB TSV DIC JSON TextAE

Id Subject Object Predicate Lexical cue
T0 23554-23557 DT denotes The
T1 23558-23568 NN denotes expression
T2 23569-23571 IN denotes of
T3 23572-23579 NN denotes FcγRIIb
T4 23580-23582 IN denotes on
T5 23583-23587 NNP denotes LSEC
T6 23588-23591 CC denotes and
T7 23592-23595 PRP-DOLLAR- denotes its
T8 23596-23602 NN denotes action
T9 23603-23605 IN denotes in
T10 23606-23609 DT denotes the
T11 23610-23620 NN denotes “sweeping”
T12 23621-23623 CC denotes or
T13 23624-23631 NN denotes removal
T14 23632-23634 IN denotes of
T15 23635-23640 JJ denotes small
T16 23641-23647 JJ denotes immune
T17 23648-23657 NNS denotes complexes
T18 23658-23661 VBZ denotes has
T19 23662-23668 VBN denotes opened
T20 23669-23671 RP denotes up
T21 23672-23675 JJ denotes new
T22 23676-23689 NNS denotes possibilities
T23 23690-23693 IN denotes for
T24 23694-23697 DT denotes the
T25 23698-23709 NN denotes application
T26 23710-23712 IN denotes of
T27 23713-23730 VBG denotes FcγRIIb‐enhancing
T28 23731-23747 NN denotes modifications.17
T29 23748-23758 NNS denotes Antibodies
T30 23759-23761 CC denotes or
T31 23762-23764 NN denotes Fc
T32 23765-23771 NN denotes fusion
T33 23772-23780 NNS denotes proteins
T34 23780-23781 -COMMA- denotes ,
T35 23782-23787 WP-DOLLAR- denotes whose
T36 23788-23795 JJ denotes primary
T37 23796-23799 NN denotes MOA
T38 23800-23802 VBZ denotes is
T39 23803-23806 DT denotes the
T40 23807-23821 NN denotes neutralization
T41 23822-23824 IN denotes of
T42 23825-23832 JJ denotes soluble
T43 23833-23842 NNS denotes molecules
T44 23843-23847 JJ denotes such
T45 23848-23850 IN denotes as
T46 23851-23854 NN denotes IgE
T47 23855-23857 CC denotes or
T48 23858-23867 NNS denotes cytokines
T49 23867-23868 -COMMA- denotes ,
T50 23869-23872 VBP denotes are
T51 23873-23885 RB denotes particularly
T52 23886-23896 JJ denotes attractive
T53 23897-23907 NNS denotes candidates
T54 23908-23911 IN denotes for
T55 23912-23916 DT denotes this
T56 23917-23925 NN denotes approach
T57 23927-23943 NN denotes Proof‐of‐concept
T58 23944-23947 IN denotes for
T59 23948-23952 DT denotes this
T60 23953-23961 NN denotes strategy
T61 23962-23965 VBZ denotes has
T62 23966-23970 VBN denotes been
T63 23971-23983 VBN denotes demonstrated
T64 23984-23986 IN denotes in
T65 23987-23999 JJ denotes experimental
T66 24000-24009 NN denotes models.48
T67 24010-24016 RB denotes Indeed
T68 24016-24017 -COMMA- denotes ,
T69 24018-24022 DT denotes this
T70 24023-24026 MD denotes may
T71 24027-24029 VB denotes be
T72 24030-24031 DT denotes a
T73 24032-24043 JJ denotes significant
T74 24044-24053 NN denotes component
T75 24054-24056 IN denotes of
T76 24057-24060 DT denotes the
T77 24061-24066 JJ denotes rapid
T78 24067-24080 NN denotes disappearance
T79 24081-24083 IN denotes of
T80 24084-24087 NN denotes IgE
T81 24088-24092 IN denotes from
T82 24093-24096 DT denotes the
T83 24097-24108 NN denotes circulation
T84 24109-24111 IN denotes of
T85 24112-24120 NNS denotes patients
T86 24121-24128 VBN denotes treated
T87 24129-24133 IN denotes with
T88 24134-24137 DT denotes the
T89 24138-24146 NN denotes anti‐IgE
T90 24147-24155 NN denotes XmAb7195
T91 24156-24166 VBG denotes containing
T92 24167-24170 DT denotes the
T93 24171-24178 NN denotes FcγRIIb
T94 24179-24188 VBG denotes enhancing
T95 24189-24195 NNP denotes “SELF”
T96 24196-24209 NNS denotes modifications
T97 24209-24210 -COMMA- denotes ,
T98 24211-24213 IN denotes as
T99 24214-24223 VBN denotes described
T100 24224-24234 RB denotes previously
T101 24237-24243 JJ denotes Immune
T102 24244-24251 NN denotes agonism
T103 24252-24259 IN denotes through
T104 24260-24264 NN denotes FcγR
T105 24265-24276 NN denotes scaffolding
T106 24277-24286 JJ denotes Agonistic
T107 24287-24291 NNS denotes mAbs
T108 24292-24298 VBP denotes induce
T109 24299-24308 NNS denotes responses
T110 24309-24311 IN denotes in
T111 24312-24318 NN denotes target
T112 24319-24324 NNS denotes cells
T113 24325-24327 IN denotes by
T114 24328-24339 VBG denotes stimulating
T115 24340-24349 NN denotes signaling
T116 24350-24352 IN denotes of
T117 24353-24358 PRP-DOLLAR- denotes their
T118 24359-24368 JJ denotes molecular
T119 24369-24375 NN denotes target
T120 24377-24386 RB denotes Typically
T121 24386-24387 -COMMA- denotes ,
T122 24388-24392 DT denotes this
T123 24393-24395 VBZ denotes is
T124 24396-24398 TO denotes to
T125 24399-24405 CC denotes either
T126 24406-24413 VB denotes enhance
T127 24414-24423 NN denotes antitumor
T128 24424-24432 NN denotes immunity
T129 24433-24435 IN denotes by
T130 24436-24444 VBG denotes engaging
T131 24445-24458 JJ denotes costimulatory
T132 24459-24468 NNS denotes molecules
T133 24469-24471 IN denotes on
T134 24472-24490 JJ denotes antigen‐presenting
T135 24491-24496 NNS denotes cells
T136 24497-24499 CC denotes or
T137 24500-24501 NN denotes T
T138 24502-24507 NNS denotes cells
T139 24508-24509 -LRB- denotes (
T140 24509-24513 FW denotes i.e.
T141 24514-24518 NN denotes CD40
T142 24518-24519 -COMMA- denotes ,
T143 24520-24525 NN denotes 4‐1BB
T144 24525-24526 -COMMA- denotes ,
T145 24527-24531 NN denotes OX40
T146 24531-24532 -RRB- denotes )
T147 24533-24535 CC denotes or
T148 24536-24543 VB denotes promote
T149 24544-24553 NN denotes apoptosis
T150 24554-24556 IN denotes by
T151 24557-24565 VBG denotes engaging
T152 24566-24571 NN denotes death
T153 24572-24581 NNS denotes receptors
T154 24582-24584 IN denotes on
T155 24585-24591 NN denotes cancer
T156 24592-24597 NNS denotes cells
T157 24598-24599 -LRB- denotes (
T158 24599-24603 FW denotes i.e.
T159 24604-24607 NN denotes DR4
T160 24607-24608 -COMMA- denotes ,
T161 24609-24612 NN denotes DR5
T162 24612-24613 -COMMA- denotes ,
T163 24614-24617 NN denotes Fas
T164 24617-24618 -RRB- denotes )
T165 24623-24626 DT denotes The
T166 24627-24631 NN denotes role
T167 24632-24634 IN denotes of
T168 24635-24639 NN denotes FcγR
T169 24640-24642 IN denotes in
T170 24643-24646 DT denotes the
T171 24647-24653 NN denotes action
T172 24654-24656 IN denotes of
T173 24657-24662 DT denotes these
T174 24663-24668 NNS denotes types
T175 24669-24671 IN denotes of
T176 24672-24676 NNS denotes mAbs
T177 24677-24684 VBZ denotes appears
T178 24685-24687 TO denotes to
T179 24688-24690 VB denotes be
T180 24691-24700 RB denotes primarily
T181 24701-24703 IN denotes as
T182 24704-24705 DT denotes a
T183 24706-24714 NN denotes scaffold
T184 24716-24723 NN denotes FcγRIIb
T185 24724-24726 VBZ denotes is
T186 24727-24732 RB denotes often
T187 24733-24736 DT denotes the
T188 24737-24748 JJ denotes predominate
T189 24749-24757 NN denotes receptor
T190 24758-24766 VBN denotes involved
T191 24767-24770 CC denotes and
T192 24771-24774 DT denotes the
T193 24775-24781 NN denotes extent
T194 24782-24784 IN denotes of
T195 24785-24788 PRP-DOLLAR- denotes its
T196 24789-24800 NN denotes involvement
T197 24801-24803 VBZ denotes is
T198 24804-24811 JJ denotes complex
T199 24813-24815 IN denotes In
T200 24816-24819 DT denotes the
T201 24820-24824 NN denotes case
T202 24825-24827 IN denotes of
T203 24828-24832 NN denotes CD40
T204 24832-24833 -COMMA- denotes ,
T205 24834-24837 DT denotes the
T206 24838-24844 NN denotes degree
T207 24845-24847 IN denotes of
T208 24848-24855 NN denotes FcγRIIb
T209 24856-24867 NN denotes scaffolding
T210 24868-24875 NN denotes potency
T211 24876-24878 VBZ denotes is
T212 24879-24885 VBN denotes linked
T213 24886-24888 TO denotes to
T214 24889-24892 DT denotes the
T215 24893-24900 NN denotes epitope
T216 24901-24909 NN denotes location
T217 24910-24912 IN denotes of
T218 24913-24916 DT denotes the
T219 24917-24926 VBG denotes targeting
T220 24927-24930 NN denotes mAb
T221 24931-24935 IN denotes with
T222 24936-24943 JJR denotes greater
T223 24944-24951 NN denotes potency
T224 24952-24956 VBN denotes seen
T225 24957-24960 IN denotes for
T226 24961-24969 NN denotes membrane
T227 24970-24978 JJ denotes proximal
T228 24979-24990 NN denotes epitopes.43
T229 24990-24991 -COMMA- denotes ,
T230 24992-24995 CD denotes 117
T231 24996-24998 PRP denotes It
T232 24999-25001 VBZ denotes is
T233 25002-25006 RB denotes also
T234 25007-25017 JJ denotes noteworthy
T235 25018-25022 IN denotes that
T236 25023-25032 VBG denotes depending
T237 25033-25035 IN denotes on
T238 25036-25039 DT denotes the
T239 25040-25047 NN denotes epitope
T240 25048-25056 NN denotes location
T241 25056-25057 -COMMA- denotes ,
T242 25058-25061 DT denotes the
T243 25062-25073 NN denotes scaffolding
T244 25074-25076 IN denotes of
T245 25077-25086 NN denotes anti‐CD40
T246 25087-25091 NNS denotes mAbs
T247 25092-25095 MD denotes may
T248 25096-25103 VB denotes convert
T249 25104-25114 NN denotes antagonist
T250 25115-25119 NNS denotes mAbs
T251 25120-25122 TO denotes to
T252 25123-25132 JJ denotes agonistic
T253 25134-25145 NN denotes Engineering
T254 25146-25148 IN denotes of
T255 25149-25152 DT denotes the
T256 25153-25157 NN denotes IgG1
T257 25158-25160 NN denotes Fc
T258 25161-25167 NN denotes region
T259 25168-25171 IN denotes for
T260 25172-25180 VBN denotes enhanced
T261 25181-25187 CC denotes and/or
T262 25188-25196 JJ denotes specific
T263 25197-25204 NN denotes binding
T264 25205-25207 TO denotes to
T265 25208-25215 NN denotes FcγRIIb
T266 25216-25219 MD denotes can
T267 25220-25227 RB denotes greatly
T268 25228-25235 VB denotes improve
T269 25236-25245 JJ denotes agonistic
T270 25246-25257 NN denotes function.72
T271 25257-25258 -COMMA- denotes ,
T272 25259-25262 CD denotes 118
T273 25262-25263 -COMMA- denotes ,
T274 25264-25267 CD denotes 119
T275 25267-25268 -COMMA- denotes ,
T276 25269-25272 CD denotes 120
T277 25273-25277 JJ denotes Such
T278 25278-25287 NNS denotes mutations
T279 25288-25295 VBD denotes induced
T280 25296-25309 RB denotes significantly
T281 25310-25317 JJR denotes greater
T282 25318-25327 JJ denotes agonistic
T283 25328-25336 NN denotes activity
T284 25337-25339 IN denotes in
T285 25340-25342 DT denotes an
T286 25343-25351 NN denotes anti‐DR5
T287 25352-25357 NN denotes model
T288 25358-25365 IN denotes through
T289 25366-25375 VBN denotes increased
T290 25376-25385 NN denotes induction
T291 25386-25388 IN denotes of
T292 25389-25398 JJ denotes apoptotic
T293 25399-25404 NN denotes death
T294 25405-25408 CC denotes and
T295 25409-25418 VBD denotes decreased
T296 25419-25424 NN denotes tumor
T297 25425-25431 NN denotes growth
T298 25432-25440 VBN denotes compared
T299 25441-25445 IN denotes with
T300 25446-25456 JJ denotes unmodified
T301 25457-25465 NN denotes IgG1.121
T302 25466-25469 DT denotes The
T303 25470-25476 NNP denotes “SELF”
T304 25477-25490 NNS denotes modifications
T305 25491-25495 WDT denotes that
T306 25496-25508 RB denotes dramatically
T307 25509-25512 CC denotes and
T308 25513-25524 RB denotes selectively
T309 25525-25533 VBP denotes increase
T310 25534-25542 NN denotes affinity
T311 25543-25546 IN denotes for
T312 25547-25554 NN denotes FcγRIIb
T313 25555-25559 VBP denotes have
T314 25560-25564 RB denotes also
T315 25565-25569 VBN denotes been
T316 25570-25574 VBN denotes used
T317 25575-25577 TO denotes to
T318 25578-25585 VB denotes enhance
T319 25586-25592 JJ denotes immune
T320 25593-25600 NN denotes agonism
T321 25601-25603 IN denotes in
T322 25604-25606 DT denotes an
T323 25607-25616 NN denotes anti‐OX40
T324 25617-25626 NN denotes model.122
T325 25627-25630 DT denotes The
T326 25631-25647 NN denotes incorporation of
T327 25648-25651 DT denotes the
T328 25652-25653 -DQS- denotes "
T329 25653-25656 NN denotes V12
T330 25656-25657 '' denotes "
T331 25658-25660 NN denotes Fc
T332 25661-25670 NNS denotes mutations
T333 25671-25675 IN denotes into
T334 25676-25680 NN denotes IgG1
T335 25681-25693 RB denotes specifically
T336 25694-25701 VBP denotes enhance
T337 25702-25709 NN denotes FcγRIIb
T338 25710-25721 NN denotes interaction
T339 25722-25730 RB denotes 200‐fold
T340 25730-25731 -COMMA- denotes ,
T341 25732-25742 VBG denotes conferring
T342 25743-25746 DT denotes the
T343 25747-25755 VBN denotes enhanced
T344 25756-25765 JJ denotes agonistic
T345 25766-25774 NN denotes activity
T346 25775-25777 IN denotes of
T347 25778-25780 DT denotes an
T348 25781-25791 NN denotes anti‐CD137
T349 25792-25800 NN denotes antibody
T350 25801-25804 CC denotes and
T351 25805-25807 DT denotes an
T352 25808-25817 NN denotes anti‐OX40
T353 25818-25825 NN denotes mAb.115
T354 25825-25826 -COMMA- denotes ,
T355 25827-25830 CD denotes 122
R0 T1 T0 arg1Of expression,The
R1 T1 T2 arg1Of expression,of
R10 T12 T10 arg1Of or,the
R100 T94 T97 arg1Of enhancing,","
R101 T94 T98 arg1Of enhancing,as
R102 T99 T98 arg2Of described,as
R103 T99 T100 arg1Of described,previously
R104 T102 T101 arg1Of agonism,Immune
R105 T102 T103 arg1Of agonism,through
R106 T105 T103 arg2Of scaffolding,through
R107 T105 T104 arg1Of scaffolding,FcγR
R108 T107 T106 arg1Of mAbs,Agonistic
R109 T107 T108 arg1Of mAbs,induce
R11 T11 T12 arg1Of “sweeping”,or
R110 T109 T108 arg2Of responses,induce
R111 T109 T110 arg1Of responses,in
R112 T112 T110 arg2Of cells,in
R113 T112 T111 arg1Of cells,target
R114 T108 T113 arg1Of induce,by
R115 T114 T113 arg2Of stimulating,by
R116 T107 T114 arg1Of mAbs,stimulating
R117 T115 T114 arg2Of signaling,stimulating
R118 T115 T116 arg1Of signaling,of
R119 T119 T116 arg2Of target,of
R12 T13 T12 arg2Of removal,or
R120 T119 T117 arg1Of target,their
R121 T119 T118 arg1Of target,molecular
R122 T123 T120 arg1Of is,Typically
R123 T123 T121 arg1Of is,","
R124 T122 T123 arg1Of this,is
R125 T147 T123 arg2Of or,is
R126 T147 T124 arg1Of or,to
R127 T147 T125 arg1Of or,either
R128 T128 T126 arg2Of immunity,enhance
R129 T128 T127 arg1Of immunity,antitumor
R13 T12 T14 arg1Of or,of
R130 T126 T129 arg1Of enhance,by
R131 T130 T129 arg2Of engaging,by
R132 T132 T130 arg2Of molecules,engaging
R133 T132 T131 arg1Of molecules,costimulatory
R134 T132 T133 arg1Of molecules,on
R135 T136 T133 arg2Of or,on
R136 T135 T134 arg1Of cells,antigen‐presenting
R137 T135 T136 arg1Of cells,or
R138 T138 T136 arg2Of cells,or
R139 T138 T137 arg1Of cells,T
R14 T17 T14 arg2Of complexes,of
R140 T136 T139 arg1Of or,(
R141 T142 T139 arg2Of ",",(
R142 T146 T139 arg3Of ),(
R143 T142 T140 arg1Of ",",i.e.
R144 T141 T142 arg1Of CD40,","
R145 T143 T142 arg2Of 4‐1BB,","
R146 T142 T144 arg1Of ",",","
R147 T145 T144 arg2Of OX40,","
R148 T126 T147 arg1Of enhance,or
R149 T148 T147 arg2Of promote,or
R15 T17 T15 arg1Of complexes,small
R150 T149 T148 arg2Of apoptosis,promote
R151 T148 T150 arg1Of promote,by
R152 T151 T150 arg2Of engaging,by
R153 T153 T151 arg2Of receptors,engaging
R154 T153 T152 arg1Of receptors,death
R155 T153 T154 arg1Of receptors,on
R156 T156 T154 arg2Of cells,on
R157 T156 T155 arg1Of cells,cancer
R158 T156 T157 arg1Of cells,(
R159 T159 T157 arg2Of DR4,(
R16 T17 T16 arg1Of complexes,immune
R160 T164 T157 arg3Of ),(
R161 T159 T158 arg1Of DR4,i.e.
R162 T159 T160 arg1Of DR4,","
R163 T161 T160 arg2Of DR5,","
R164 T159 T162 arg1Of DR4,","
R165 T163 T162 arg2Of Fas,","
R166 T166 T165 arg1Of role,The
R167 T166 T167 arg1Of role,of
R168 T168 T167 arg2Of FcγR,of
R169 T166 T169 arg1Of role,in
R17 T6 T18 arg1Of and,has
R170 T171 T169 arg2Of action,in
R171 T171 T170 arg1Of action,the
R172 T171 T172 arg1Of action,of
R173 T174 T172 arg2Of types,of
R174 T174 T173 arg1Of types,these
R175 T174 T175 arg1Of types,of
R176 T176 T175 arg2Of mAbs,of
R177 T166 T177 arg1Of role,appears
R178 T179 T177 arg2Of be,appears
R179 T179 T178 arg1Of be,to
R18 T19 T18 arg2Of opened,has
R180 T166 T179 arg1Of role,be
R181 T181 T179 arg2Of as,be
R182 T181 T180 arg1Of as,primarily
R183 T166 T181 arg1Of role,as
R184 T183 T181 arg2Of scaffold,as
R185 T183 T182 arg1Of scaffold,a
R186 T184 T185 arg1Of FcγRIIb,is
R187 T189 T185 arg2Of receptor,is
R188 T185 T186 arg1Of is,often
R189 T189 T187 arg1Of receptor,the
R19 T6 T19 arg1Of and,opened
R190 T189 T188 arg1Of receptor,predominate
R191 T189 T190 arg2Of receptor,involved
R192 T185 T191 arg1Of is,and
R193 T197 T191 arg2Of is,and
R194 T193 T192 arg1Of extent,the
R195 T193 T194 arg1Of extent,of
R196 T196 T194 arg2Of involvement,of
R197 T196 T195 arg1Of involvement,its
R198 T193 T197 arg1Of extent,is
R199 T198 T197 arg2Of complex,is
R2 T3 T2 arg2Of FcγRIIb,of
R20 T22 T19 arg2Of possibilities,opened
R200 T193 T198 arg1Of extent,complex
R201 T212 T199 arg1Of linked,In
R202 T201 T199 arg2Of case,In
R203 T201 T200 arg1Of case,the
R204 T201 T202 arg1Of case,of
R205 T203 T202 arg2Of CD40,of
R206 T212 T204 arg1Of linked,","
R207 T206 T205 arg1Of degree,the
R208 T206 T207 arg1Of degree,of
R209 T210 T207 arg2Of potency,of
R21 T19 T20 arg1Of opened,up
R210 T210 T208 arg1Of potency,FcγRIIb
R211 T210 T209 arg1Of potency,scaffolding
R212 T206 T211 arg1Of degree,is
R213 T212 T211 arg2Of linked,is
R214 T232 T211 modOf is,is
R215 T206 T212 arg2Of degree,linked
R216 T212 T213 arg1Of linked,to
R217 T216 T213 arg2Of location,to
R218 T216 T214 arg1Of location,the
R219 T216 T215 arg1Of location,epitope
R22 T22 T21 arg1Of possibilities,new
R220 T216 T217 arg1Of location,of
R221 T219 T217 arg2Of targeting,of
R222 T219 T218 arg1Of targeting,the
R223 T218 T219 arg1Of the,targeting
R224 T220 T219 arg2Of mAb,targeting
R225 T219 T221 arg1Of targeting,with
R226 T223 T221 arg2Of potency,with
R227 T223 T222 arg1Of potency,greater
R228 T223 T224 arg2Of potency,seen
R229 T224 T225 arg1Of seen,for
R23 T22 T23 arg1Of possibilities,for
R230 T228 T225 arg2Of epitopes.43,for
R231 T228 T226 arg1Of epitopes.43,membrane
R232 T228 T227 arg1Of epitopes.43,proximal
R233 T216 T229 arg1Of location,","
R234 T230 T229 arg2Of 117,","
R235 T248 T231 arg1Of convert,It
R236 T248 T232 arg1Of convert,is
R237 T234 T232 arg2Of noteworthy,is
R238 T232 T233 arg1Of is,also
R239 T248 T234 arg1Of convert,noteworthy
R24 T25 T23 arg2Of application,for
R240 T248 T235 arg1Of convert,that
R241 T248 T236 arg1Of convert,depending
R242 T237 T236 arg2Of on,depending
R243 T240 T237 arg2Of location,on
R244 T240 T238 arg1Of location,the
R245 T240 T239 arg1Of location,epitope
R246 T248 T241 arg1Of convert,","
R247 T243 T242 arg1Of scaffolding,the
R248 T243 T244 arg1Of scaffolding,of
R249 T246 T244 arg2Of mAbs,of
R25 T25 T24 arg1Of application,the
R250 T246 T245 arg1Of mAbs,anti‐CD40
R251 T243 T247 arg1Of scaffolding,may
R252 T248 T247 arg2Of convert,may
R253 T243 T248 arg1Of scaffolding,convert
R254 T250 T248 arg2Of mAbs,convert
R255 T250 T249 arg1Of mAbs,antagonist
R256 T248 T251 arg1Of convert,to
R257 T252 T251 arg2Of agonistic,to
R258 T253 T254 arg1Of Engineering,of
R259 T258 T254 arg2Of region,of
R26 T25 T26 arg1Of application,of
R260 T258 T255 arg1Of region,the
R261 T258 T256 arg1Of region,IgG1
R262 T258 T257 arg1Of region,Fc
R263 T258 T259 arg1Of region,for
R264 T263 T259 arg2Of binding,for
R265 T263 T260 arg1Of binding,enhanced
R266 T260 T261 arg1Of enhanced,and/or
R267 T262 T261 arg2Of specific,and/or
R268 T263 T262 arg1Of binding,specific
R269 T263 T264 arg1Of binding,to
R27 T30 T26 arg2Of or,of
R270 T265 T264 arg2Of FcγRIIb,to
R271 T253 T266 arg1Of Engineering,can
R272 T268 T266 arg2Of improve,can
R273 T268 T267 arg1Of improve,greatly
R274 T253 T268 arg1Of Engineering,improve
R275 T270 T268 arg2Of function.72,improve
R276 T270 T269 arg1Of function.72,agonistic
R277 T270 T271 arg1Of function.72,","
R278 T272 T271 arg2Of 118,","
R279 T270 T273 arg1Of function.72,","
R28 T29 T27 arg1Of Antibodies,FcγRIIb‐enhancing
R280 T274 T273 arg2Of 119,","
R281 T268 T275 arg1Of improve,","
R282 T294 T275 arg2Of and,","
R283 T278 T276 arg1Of mutations,120
R284 T278 T277 arg1Of mutations,Such
R285 T278 T279 arg1Of mutations,induced
R286 T283 T279 arg2Of activity,induced
R287 T281 T280 arg1Of greater,significantly
R288 T283 T281 arg1Of activity,greater
R289 T283 T282 arg1Of activity,agonistic
R29 T29 T28 arg1Of Antibodies,modifications.17
R290 T279 T284 arg1Of induced,in
R291 T287 T284 arg2Of model,in
R292 T287 T285 arg1Of model,an
R293 T287 T286 arg1Of model,anti‐DR5
R294 T279 T288 arg1Of induced,through
R295 T290 T288 arg2Of induction,through
R296 T290 T289 arg2Of induction,increased
R297 T290 T291 arg1Of induction,of
R298 T293 T291 arg2Of death,of
R299 T293 T292 arg1Of death,apoptotic
R3 T1 T4 arg1Of expression,on
R30 T29 T30 arg1Of Antibodies,or
R300 T279 T294 arg1Of induced,and
R301 T295 T294 arg2Of decreased,and
R302 T278 T295 arg1Of mutations,decreased
R303 T297 T295 arg2Of growth,decreased
R304 T297 T296 arg1Of growth,tumor
R305 T295 T298 arg1Of decreased,compared
R306 T299 T298 arg2Of with,compared
R307 T301 T299 arg2Of IgG1.121,with
R308 T301 T300 arg1Of IgG1.121,unmodified
R309 T304 T302 arg1Of modifications,The
R31 T33 T30 arg2Of proteins,or
R310 T304 T303 arg1Of modifications,“SELF”
R311 T304 T305 arg1Of modifications,that
R312 T309 T306 arg1Of increase,dramatically
R313 T306 T307 arg1Of dramatically,and
R314 T308 T307 arg2Of selectively,and
R315 T309 T308 arg1Of increase,selectively
R316 T304 T309 arg1Of modifications,increase
R317 T310 T309 arg2Of affinity,increase
R318 T310 T311 arg1Of affinity,for
R319 T312 T311 arg2Of FcγRIIb,for
R32 T33 T31 arg1Of proteins,Fc
R320 T304 T313 arg1Of modifications,have
R321 T316 T313 arg2Of used,have
R322 T316 T314 arg1Of used,also
R323 T304 T315 arg1Of modifications,been
R324 T316 T315 arg2Of used,been
R325 T304 T316 arg2Of modifications,used
R326 T318 T316 arg3Of enhance,used
R327 T318 T317 arg1Of enhance,to
R328 T304 T318 arg1Of modifications,enhance
R329 T301 T318 arg2Of IgG1.121,enhance
R33 T33 T32 arg1Of proteins,fusion
R330 T320 T319 arg1Of agonism,immune
R331 T299 T320 arg1Of with,agonism
R332 T320 T321 arg1Of agonism,in
R333 T324 T321 arg2Of model.122,in
R334 T324 T322 arg1Of model.122,an
R335 T324 T323 arg1Of model.122,anti‐OX40
R336 T326 T325 arg1Of incorporation of,The
R337 T336 T326 arg1Of enhance,incorporation of
R338 T332 T327 arg1Of mutations,the
R339 T332 T328 arg1Of mutations,""""
R34 T22 T34 arg1Of possibilities,","
R340 T332 T329 arg1Of mutations,V12
R341 T332 T330 arg1Of mutations,""""
R342 T332 T331 arg1Of mutations,Fc
R343 T332 T333 arg1Of mutations,into
R344 T334 T333 arg2Of IgG1,into
R345 T336 T335 arg1Of enhance,specifically
R346 T332 T336 arg1Of mutations,enhance
R347 T338 T336 arg2Of interaction,enhance
R348 T338 T337 arg1Of interaction,FcγRIIb
R349 T336 T339 arg1Of enhance,200‐fold
R35 T37 T35 arg1Of MOA,whose
R350 T336 T340 arg1Of enhance,","
R351 T332 T341 arg1Of mutations,conferring
R352 T350 T341 arg2Of and,conferring
R353 T336 T341 modOf enhance,conferring
R354 T345 T342 arg1Of activity,the
R355 T345 T343 arg2Of activity,enhanced
R356 T345 T344 arg1Of activity,agonistic
R357 T345 T346 arg1Of activity,of
R358 T349 T346 arg2Of antibody,of
R359 T349 T347 arg1Of antibody,an
R36 T22 T35 arg2Of possibilities,whose
R360 T349 T348 arg1Of antibody,anti‐CD137
R361 T345 T350 arg1Of activity,and
R362 T353 T350 arg2Of mAb.115,and
R363 T353 T351 arg1Of mAb.115,an
R364 T353 T352 arg1Of mAb.115,anti‐OX40
R365 T353 T354 arg1Of mAb.115,","
R366 T355 T354 arg2Of 122,","
R37 T37 T36 arg1Of MOA,primary
R38 T37 T38 arg1Of MOA,is
R39 T40 T38 arg2Of neutralization,is
R4 T5 T4 arg2Of LSEC,on
R40 T40 T39 arg1Of neutralization,the
R41 T40 T41 arg1Of neutralization,of
R42 T43 T41 arg2Of molecules,of
R43 T43 T42 arg1Of molecules,soluble
R44 T45 T44 arg1Of as,such
R45 T43 T45 arg1Of molecules,as
R46 T47 T45 arg2Of or,as
R47 T46 T47 arg1Of IgE,or
R48 T48 T47 arg2Of cytokines,or
R49 T38 T49 arg1Of is,","
R5 T1 T6 arg1Of expression,and
R50 T50 T49 arg2Of are,","
R51 T37 T50 arg1Of MOA,are
R52 T53 T50 arg2Of candidates,are
R53 T52 T51 arg1Of attractive,particularly
R54 T53 T52 arg1Of candidates,attractive
R55 T53 T54 arg1Of candidates,for
R56 T56 T54 arg2Of approach,for
R57 T56 T55 arg1Of approach,this
R58 T57 T58 arg1Of Proof‐of‐concept,for
R59 T60 T58 arg2Of strategy,for
R6 T8 T6 arg2Of action,and
R60 T60 T59 arg1Of strategy,this
R61 T57 T61 arg1Of Proof‐of‐concept,has
R62 T63 T61 arg2Of demonstrated,has
R63 T57 T62 arg1Of Proof‐of‐concept,been
R64 T63 T62 arg2Of demonstrated,been
R65 T57 T63 arg2Of Proof‐of‐concept,demonstrated
R66 T63 T64 arg1Of demonstrated,in
R67 T66 T64 arg2Of models.48,in
R68 T66 T65 arg1Of models.48,experimental
R69 T66 T67 arg1Of models.48,Indeed
R7 T8 T7 arg1Of action,its
R70 T63 T68 arg1Of demonstrated,","
R71 T71 T68 arg2Of be,","
R72 T69 T70 arg1Of this,may
R73 T71 T70 arg2Of be,may
R74 T69 T71 arg1Of this,be
R75 T74 T71 arg2Of component,be
R76 T74 T72 arg1Of component,a
R77 T74 T73 arg1Of component,significant
R78 T74 T75 arg1Of component,of
R79 T78 T75 arg2Of disappearance,of
R8 T8 T9 arg1Of action,in
R80 T78 T76 arg1Of disappearance,the
R81 T78 T77 arg1Of disappearance,rapid
R82 T78 T79 arg1Of disappearance,of
R83 T80 T79 arg2Of IgE,of
R84 T80 T81 arg1Of IgE,from
R85 T83 T81 arg2Of circulation,from
R86 T83 T82 arg1Of circulation,the
R87 T83 T84 arg1Of circulation,of
R88 T85 T84 arg2Of patients,of
R89 T85 T86 arg2Of patients,treated
R9 T12 T9 arg2Of or,in
R90 T86 T87 arg1Of treated,with
R91 T90 T87 arg2Of XmAb7195,with
R92 T90 T88 arg1Of XmAb7195,the
R93 T90 T89 arg1Of XmAb7195,anti‐IgE
R94 T90 T91 arg1Of XmAb7195,containing
R95 T93 T91 arg2Of FcγRIIb,containing
R96 T93 T92 arg1Of FcγRIIb,the
R97 T93 T94 arg1Of FcγRIIb,enhancing
R98 T96 T94 arg2Of modifications,enhancing
R99 T96 T95 arg1Of modifications,“SELF”